Carrier Registration Group Schedules Routine Meeting
Published Date: 5/19/2026
Notice
Summary
The Unified Carrier Registration (UCR) Task Force is holding a public meeting on May 27, 2026, to discuss updates to the UCR Plan and Agreement that affect carriers who register for interstate transportation. They’ll review past meeting notes, consider changes, and set the stage for smoother registration processes. No new fees or costs are mentioned, but staying tuned is key for carriers and stakeholders.
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-22276, Sunshine Act Meetings
The Unified Carrier Registration (UCR) Enforcement Subcommittee is holding an open meeting on November 5, 2026, to discuss and improve carrier registration enforcement. This affects trucking companies and related businesses by focusing on compliance and planning new awareness efforts for 2027. The meeting is free to join by phone or Zoom, keeping everyone in the loop without any new fees announced yet.
2026-21956, Sunshine Act Meetings
The Unified Carrier Registration (UCR) Board is holding an open meeting on October 28, 2026, to discuss updates and possible changes to the UCR Agreement that affects carriers registering for interstate transportation. They’ll review past meeting minutes, hear reports, and consider new rules that could impact how carriers register and pay fees. This meeting is open to the public and accessible by phone and Zoom, keeping everyone in the loop and ready for any upcoming changes.
2026-20759, Sunshine Act Meetings
The Unified Carrier Registration Plan is holding a public meeting on October 15, 2026, to discuss updates on registration fees for 2027 and 2028, review past revenues, and share a 2025 financial audit update. This affects carriers who register under the plan and anyone interested can join via phone or Zoom. No new costs are announced yet, but fee updates are on the agenda.
2026-15151, Sunshine Act Meetings
2026-14608, Board of Directors; Request for Nomination
The Unified Carrier Registration Plan is looking for a new board member from the motor carrier industry to fill a spot until May 31, 2027. If you’re part of a national trade group for property motor carriers, you can apply by August 28, 2026. This role helps shape rules and fees for companies that move goods across state lines.
2026-13768, Sunshine Act Meetings
The Unified Carrier Registration (UCR) Finance Subcommittee is holding an open meeting on July 9, 2026, to discuss updates on registration fees for 2027 and 2028. This affects trucking companies and carriers who pay these fees. The meeting is free to join online or by phone, and any fee changes could impact how much carriers pay next year.
Previous / Next Documents
Previous: 2026-10007, Certain Corrosion Inhibitors From the People's Republic of China: Final Results of the Expedited First Sunset Review of the Antidumping Duty Order
The U.S. Department of Commerce decided to keep the special taxes on certain corrosion inhibitors from China because stopping them could let unfairly cheap products flood the market again. This affects Chinese exporters and U.S. manufacturers who make similar products. The decision started on May 19, 2026, and means these extra costs will stay in place to protect American businesses.
Next: 2026-10010, Certain Drug Products Containing C-Type Natriuretic Peptide Variants, and Components Thereof; Notice of a Commission Determination Not To Review an Initial Determination Amending the Complaint and Notice of Investigation
The U.S. International Trade Commission has approved updating the investigation papers to reflect that Ascendis Pharma changed its name to Ascendis Pharma, LLC. This affects companies involved in a patent dispute over certain drug products with C-type natriuretic peptide variants. No delays or extra costs are expected, so the investigation keeps moving forward smoothly.